Search Results - bortezomib

2 Results Sort By:
Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders
The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...
Published: 10/28/2024   |   Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner
Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology
Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers
The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...
Published: 10/28/2024   |   Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner
Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology